Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Arformoterol tartrate
Drug ID BADD_D00160
Description Arformoterol is a bronchodilator. It works by relaxing muscles in the airways to improve breathing. Arformoterol inhalation is used to prevent bronchoconstriction in people with chronic obstructive pulmonary disease, including chronic bronchitis and emphysema. The use of arformoterol is pending revision due to safety concerns in regards to an increased risk of severe exacerbation of asthma symptoms, leading to hospitalization as well as death in some patients using long acting beta agonists for the treatment of asthma.
Indications and Usage A bronchodilator used for the long term, symptomatic treatment of reversible bronchoconstriction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema.
Marketing Status approved; investigational
ATC Code R03CC15; R03AC13
DrugBank ID DB01274
KEGG ID D02981
MeSH ID D000068759
PubChem ID 9827062
TTD Drug ID D0D1DI
NDC Product Code 64567-0022; 62332-633; 62756-277; 66039-909; 70748-175; 63402-911; 14501-0077; 0093-5955; 50384-4279; 70756-612; 69097-168; 53104-7731
UNII 5P8VJ2I235
Synonyms Formoterol Fumarate | Formoterol Fumarate, ((R*,R*)-(+-))-isomer | 3-Formylamino-4-hydroxy-alpha-(N-1-methyl-2-p-methoxyphenethylaminomethyl)benzyl alcohol.hemifumarate | BD 40A | Formoterol | Eformoterol | Oxis | Arformoterol | Formoterol, ((R*,R*)-(+-))-isomer | Foradil
Chemical Information
Molecular Formula C23H30N2O10
CAS Registry Number 200815-49-2
SMILES CC(CC1=CC=C(C=C1)OC)NCC(C2=CC(=C(C=C2)O)NC=O)O.C(C(C(=O)O)O)(C(=O)O)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Neoplasm16.16.02.001---
Nephrolithiasis20.04.01.002--
Nervousness19.06.02.003---
Nocturia20.02.03.001---
Oedema08.01.07.006; 14.05.06.010---
Oedema peripheral02.05.04.007; 08.01.07.007; 14.05.06.011--
Oral candidiasis07.05.07.001; 11.03.03.004---
Pain08.01.08.004--
Palpitations02.11.04.012--
Paralysis17.01.04.004---
Pelvic pain07.01.06.012; 20.02.03.007; 21.10.01.001--
Prostatic specific antigen increased13.23.01.003---
Pyrexia08.05.02.003--
Pyuria11.01.08.043; 20.08.02.016---
Rash23.03.13.001---
Rectal haemorrhage07.12.03.001; 24.07.02.018--
Respiratory disorder22.02.07.002---
Retroperitoneal haemorrhage07.07.02.002; 12.01.17.018; 24.07.01.017--
Rheumatoid arthritis10.04.06.001; 15.01.03.001---
Sinusitis11.01.13.005; 22.07.03.007--
Skin discolouration23.03.03.005---
Skin hypertrophy23.01.04.002---
Somnolence17.02.04.006; 19.02.05.003--
Supraventricular tachycardia02.03.03.012--
Tachycardia02.03.02.007---
Tendinous contracture15.07.01.001---
Tooth abscess07.09.01.003; 11.01.04.003---
Tremor17.01.06.002--
Urinary tract disorder20.08.01.001---
Urine abnormality20.02.01.013---
The 3th Page    First    Pre   3 4    Next   Last    Total 4 Pages